Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T21:57:52.627Z.
Calculation as of: 2026-10-06T21:57:52.627Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f9e30a8d320e3cb26c3b838953cbb8bfe3908fe2cbbcdc0c218fd5db8a33f332
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Pulsenmore Ltd. Ordinary Shares
Market Cap
$14.05M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.86M
EV/Sales Ratio
9.64x
TTM Avg
6.53x
3Y Avg
5.18x
5Y Avg
1267.27x
Market Cap
$14.46M
EV/Sales Ratio
50.78x
TTM Avg
16.53x
3Y Avg
4.93x
5Y Avg
3.45x
Market Cap
$14.73M
EV/Sales Ratio
1.20x
TTM Avg
1.84x
3Y Avg
1.65x
5Y Avg
2.08x
Market Cap
$13.30M
EV/Sales Ratio
62.14x
TTM Avg
135.82x
3Y Avg
650.44x
5Y Avg
556.96x
Market Cap
$13.20M
EV/Sales Ratio
0.47x
TTM Avg
1.89x
3Y Avg
1.89x
5Y Avg
1.89x
Market Cap
$14.94M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pulsenmore Ltd. Ordinary Shares (PLSM) | $14.05M | N/A | N/A | N/A | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.86M | 9.64x | 6.53x | 5.18x | 1267.27x |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.75M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $14.46M | 50.78x | 16.53x | 4.93x | 3.45x |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.73M | 1.20x | 1.84x | 1.65x | 2.08x |
| IN8bio, Inc. (INAB)vs › | $13.33M | N/A | N/A | N/A | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.30M | 62.14x | 135.82x | 650.44x | 556.96x |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.20M | 0.47x | 1.89x | 1.89x | 1.89x |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.94M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $13.11M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
